Sydney, Australia 27 October 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the registrational Phase III CLARIFY trial (NCT06056830)1 has dosed the planned target of 383 participants in the study. CLARIFY…
Sydney, Australia 8 October 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the recruitment target of the Cohort Expansion (Main Group) of the Phase I/IIa SECuRE trial has been achieved. The…
Sydney, Australia 21 September 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce, in accordance with Listing Rule 3.13.1, that the date of its AGM will be 25 November 2026. In accordance with…